In preparation for studies of noradrenergic activity in anticipatory nausea and vomiting, we performed an open-dose study of clonidine to examine dose-toxicity relationships and indications of antiemetic activity. Nine patients, three each at 0.1, 0.2, and 0.4 mg/day, received clonidine twice a day for 5 days before chemotherapy. Unwanted effects, principally blood pressure reduction, dry mouth, and sedation, accumulated between 4 and 5 μg/kg/day. Four of eight evaluable patients had no anticipatory symptoms on clonidine. It is concluded that clonidine, at a dose of 4 μg/kg/day, might safely probe the role of noradrenergic activity in anticipatory nausea and vomiting.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|State||Published - 1987|
ASJC Scopus subject areas
- Cancer Research